Pyrosequencing Analysis of MGMT Promoter Methylation in Meningioma.

ABSTRACT:

Background

Methylation of the O⁶-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictor of response to the DNA-alkylating agent temozolomide in patients with glioblastoma.

Materials and methods

Pyrosequencing analysis was used to determine the MGMT promoter methylation status in 61 meningiomas, to clarify whether it might have a predictive role.

Results

Only two tumors (3%) had a mean methylation frequency higher than the cut-off value of 10% for the four CpG sites examined.

Conclusion

The methylation of the MGMT promoter is uncommon, or occurs at a low frequency in meningiomas. There is no convincing rationale to test such tumors for their MGMT methylation status in a clinical setting.

SUBMITTER: Panagopoulos I 

PROVIDER: S-EPMC6199576 | biostudies-literature | 2018 Sep-Oct

REPOSITORIES: biostudies-literature